Meta tag

Cardiovascular Risk

2 articles

db#5220

One gene-editing dose cut LDL cholesterol by 62 percent

An experimental gene-editing drug cut LDL cholesterol by 62 percent after a single dose in a small trial, but proof of effect is not yet proof of broad safety.

28 May 2026

Lilly says Verve gene editor cut cholesterol by 62% in early trial

MedicineRewritten

db#4804

Lilly and Verve push cholesterol care toward a one-time gene edit

Eli Lilly says a high dose of Verve’s gene-editing therapy lowered cholesterol by 62% in an early clinical trial.

25 May 2026

Meta tag

Cardiovascular Risk

2 articles

MedicineRewritten

db#5220

One gene-editing dose cut LDL cholesterol by 62 percent

An experimental gene-editing drug cut LDL cholesterol by 62 percent after a single dose in a small trial, but proof of effect is not yet proof of broad safety.

28 May 2026

MedicineRewritten

db#4804

Lilly and Verve push cholesterol care toward a one-time gene edit

Eli Lilly says a high dose of Verve’s gene-editing therapy lowered cholesterol by 62% in an early clinical trial.

25 May 2026